Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

2 hours ago 1

Robert Izquierdo, The Motley Fool

Mon, December 22, 2025 astatine 10:35 AM CST 5 min read

Cormorant Asset Management added 251,600 shares successful Rapport Therapeutics; the reported presumption worth accrued by astir $61.38 cardinal implicit the anterior quarter.
The alteration represents 0.31% of Cormorant’s reportable 13F assets nether management.
The post-trade involvement totaled 3,192,521 shares worthy $94.82 million.
Rapport Therapeutics present comprises 6.54% of AUM, making it the fund's 4th-largest holding.
These 10 stocks could mint the adjacent question of millionaires ›

Cormorant Asset Management, LP reported a bargain of 251,600 further shares of Rapport Therapeutics (NASDAQ:RAPP), arsenic disclosed successful its November 14, 2025, SEC filing. The recently reported presumption stands astatine 3,192,521 shares, valued astatine $94.82 cardinal astatine quarter-end. The commercialized accrued the involvement by astir $61.38 million, accounting for 0.31% of Cormorant’s $1.45 cardinal successful reportable U.S. equity assets.

Cormorant Asset Management, LP accrued its holding successful Rapport Therapeutics; post-trade, the presumption represents 6.54% of 13F AUM.

Top holdings aft the filing:

NASDAQ:BBOT: $207,034,119 (14.3% of AUM)
NASDAQ:ABVX: $165,555,000 (11.4% of AUM)
NASDAQ:EYPT: $118,548,000 (8.2% of AUM)
NASDAQ:RAPP: $94,817,874 (6.5% of AUM)
NASDAQ:BBIO: $72,716,000 (5.0% of AUM)

As of November 14, 2025, shares of Rapport Therapeutics were priced astatine $24.37, up 10.87% implicit the past year, underperforming the S&P 500 by 1.0 percent points.

Metric

Value

Price (as of marketplace adjacent November 14, 2025)	$24.37
Market capitalization	$1.49 billion
Net income (TTM)	($97.70 million)
One-year terms alteration (as of marketplace adjacent November 14, 2025)	10.87%

Rapport Therapeutics develops tiny molecule therapeutics targeting cardinal tense strategy (CNS) disorders, with pb candidates including RAP-219 for focal epilepsy and different CNS indications, and further programs addressing chronic symptom and proceeding disorders.
It operates arsenic a clinical-stage biopharmaceutical institution focused connected the find and improvement of proprietary cause candidates with the purpose of advancing them done objective trials and imaginable regulatory approval.
The institution targets patients suffering from CNS disorders, including epilepsy, neuropathic pain, bipolar disorder, and proceeding loss, with a superior absorption connected unmet aesculapian needs successful neurology and psychiatry.

Rapport Therapeutics is simply a clinical-stage biotechnology institution advancing a pipeline of tiny molecule medicines for cardinal tense strategy disorders. The company's strategy centers connected processing differentiated therapies with caller mechanisms of action, addressing important unmet needs successful neurology and psychiatry. With a focused portfolio and proprietary research, Rapport aims to found a competitory borderline successful the CNS therapeutics market.